Monitoring EGFR-lung cancer evolution: a possible beginning of a “methylation era” in TKI resistance prediction

The advances in scientific knowledge on biological therapies of the last two decades have impressively oriented the clinical management of non-small-cell lung cancer (NSCLC) patients. The treatment with tyrosine kinase inhibitors (TKIs) in patients harboring Epidermal Growth Factor Receptor (EGFR)-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabrizio, Federico Pio, Sparaneo, Angelo, Muscarella, Lucia Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157092/
https://www.ncbi.nlm.nih.gov/pubmed/37152062
http://dx.doi.org/10.3389/fonc.2023.1137384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157092/
https://www.ncbi.nlm.nih.gov/pubmed/37152062
http://dx.doi.org/10.3389/fonc.2023.1137384

Ejemplares similares